



**FOR IMMEDIATE RELEASE**  
**— APRIL 2024**

**CONTACT: NEIL KOSTERMAN**  
**PRESIDENT**  
**1 (608) 335-8799**  
[NEIL@NEILKO.COM](mailto:NEIL@NEILKO.COM)

## Delta Chase Announces New Patent for SAGE Rebreather™

**[Delta Chase LLC | Cincinnati Ohio]** -Delta Chase LLC announces the issuance of a new patent providing added legal protection for its exciting and powerful SAGE Rebreather™ innovation designed specifically to avoid brain damage (some know it as "concussion") from traumatic episodes such as occur on sports fields or in warfighters on the battlefield or in training. David Smith MD, the inventor, discovered two protective models from Mother Nature when doing research prior to 2010. Both models convert elastic collisions inside the cranium from inelastic to elastic collisions, which reduce SLOSH energy absorption and its damaging effects (literally allowing the impact to pass right through the brain).

Dr. Smith's first patented invention, the Qcollar™, launched commercially with FDA authorization for brain protection claims in 2022 by its licensee ([q30.com](http://q30.com)), which now has over 30 thousand users, including many in professional sports and the US military. Dr. Smith says, "This newest patent of six (6) for the SAGE Rebreather significantly increases the breadth and depth of our legal protection against copycat devices for the next 20+ years." This patent notably improves the early-stage value of DeltaChase going forward.

Besides the indicated brain protection and repair, the SAGE Rebreather device also improves health of users for over a dozen human illnesses, including sleep apnea, brain protection, TBI reversal, and recovery from traumatic episodes, altitude illness, dizzy diseases to name just a few.

Of all the potential health advances for the use of CO<sub>2</sub> modulation of the body's physiology, only the Sleep Apnea application has thus far been validated in a HUMAN clinical study and published in reputable journal(s) using a specialty CO<sub>2</sub> gas mixture that our mask mimics in use. In that one case we should be able to demonstrate equivalency to the FDA to expedite clearance to market. The rest of the applications need also to validate in their own clinical studies and then submit the FDA for their review.

DeltaChase has completed and published animal studies in collaboration with Matt Robson PhD of the Neuropharmacology Department of the University of Cincinnati demonstrating the SAGE Rebreather's PREMISE of gently and harmlessly raising one's CO<sub>2</sub> levels. This new alliance led the Neuropharmacology department to invite DrDave to present his work to their department as a whole